NovaNex | Evolution looks good on you.

Clinical Overview

Loading model

Built on science. Grounded in continuity.

The ovarian-transductive pathway (Series 1) is designed as an addition, not a replacement. It introduces integrated phallic anatomy while preserving the ovaries, uterus, fallopian tubes, and the body’s natural cycle.

The phallus is formed from a tissue-engineered graft grown from the client’s own cells, with its sensory foundation built around preserved clitoral tissue and neurovascular structures. It is integrated with the pelvic support tissues and connected to the body’s existing neurovascular structures. The urethra is extended and rerouted through the new anatomy, allowing urination through the phallus while supporting stable function, sensation, and erectile response.

A specialized reproductive gland is also introduced, allowing ejaculatory fluid to carry a mature ovum during fertile periods. This creates an additional pathway to conception with spermatogenic conversion clients (Series 2) while leaving the existing reproductive system intact.

Clients retain ovarian fertility and the ability to carry a pregnancy, while gaining erectile and ejaculatory function. For clients seeking expanded anatomy without relinquishing their existing reproductive framework, Series 1 offers the most continuity-focused pathway in the NovaNex portfolio.

Who Series 1 Is For

Designed for continuity

Series 1 may suit clients who want the added sexual, reproductive, and personal possibilities of transformation while preserving their existing ovarian and gestational biology.

It is designed for clients drawn to integrated phallic anatomy, broader compatibility, and new forms of expression, but who also want their pathway to build on the reproductive framework their body already provides.

You want expanded possibilities

You are drawn to the added sexual, reproductive, and personal possibilities that come with integrated phallic anatomy.

You value continuity

You want transformation to build on your existing reproductive biology while preserving ovarian, uterine, and gestational continuity.

You embrace sexual autonomy

You want a pathway that reflects your own sense of self, confidence, expression, and control over your body.

You want broader reproductive compatibility

You want reproductive compatibility with men and Series 2 partners while preserving your own pregnancy options.

What Changes, What Remains The Same

What Series 1 adds

Integrated erectile anatomy

A fully sensate phallus with stable erectile function.

Extended urinary pathway

The urethra is routed through the phallus for natural urinary function.

Ejaculatory function

Ovumate carrier fluid is produced continuously, with a mature ovum present during fertile periods.

Ovumate-based reproductive transfer

Adds an external route for delivering an ovum to compatible partners.

Extended sensory and vascular pathways

Existing neurovascular structures are integrated into the new anatomy.

What Series 1 preserves

Ovaries

Natural ovum production and ovarian function continue.

Uterus

Gestational structure and function remain intact.

Hormonal baseline

Female hormonal rhythms continue without routine replacement therapy.

Menstruation and ovulation

The existing menstrual and ovulatory cycle continues.

Capacity to carry a pregnancy

Clients retain the ability to conceive and carry a pregnancy.

Your Series 1 Care Pathway

1. Consultation

Your care pathway begins with a private consultation focused on your goals, medical history and reproductive priorities. We'll explain what Series 1 adds and preserves, assess whether it is the right fit for you, and answer any questions before you decide how to proceed.

Timeframe

Day 1

Duration

About 1 hour

Outcome

Pathway recommendation

What to expect

Care coordinator assigned
Goals and priorities discussed
Medical history reviewed
Pathway suitability evaluated
Questions answered
Payment and access options reviewed

The pathway includes attentive support through each stage so you can move forward with clarity and confidence.

Recovery and Clinical Confidence

Series 1 is designed for a relatively short recovery period and dependable anatomical integration. Clients remain under short-stay observation for 24–48 hours, usually return to ordinary daily routines within days, and typically receive unrestricted activity clearance around one month after treatment. Typical overall recovery usually spans 3–5 weeks. Temporary swelling, sensitivity changes, and unfamiliar everyday sensations are expected parts of early adaptation.

24–48 hours

Short-stay monitoring

Within days

Return to ordinary routines

Around day 30

Typical activity clearance

Minimal visible scarring

Precision closure

What early recovery and adaptation can feel like

1.

Mild swelling and tenderness

Light swelling, tightness, or tenderness around the treated area is normal during the first few days and typically improves quickly.

2.

Sensitivity changes

Sensation may feel unusually strong, muted, or inconsistent at first as nerves and tissues adapt, and usually settles over the following days and weeks.

3.

Urinary adjustment

Urination may feel unfamiliar while adapting to the extended urinary pathway, but these changes are usually mild and short-term.

4.

Spontaneous erections

Unexpected erections can occur during early healing and are considered a normal part of neural recovery and adaptation.

5.

Sitting, movement, and comfort

Hard seating, close pressure, or fitted clothing may feel uncomfortable briefly, and softer seating is often preferred during the first several days.

6.

Clothing and everyday fit

Most clients continue using their existing wardrobe, while some temporarily prefer looser underwear, relaxed menswear, or transformation-fit garments during early recovery while sensitivity settles.

If anything feels concerning or outside expectations, your NovaNex care team is available around the clock during early recovery.

Clinical confidence and follow-up

Series 1 combines predictive screening, personalized planning, precision closure, and structured monitoring to support rapid recovery and dependable outcomes. Most clients complete recovery without any clinical adjustment beyond routine follow-up.

Temporary adaptation concerns, such as stronger or quieter sensitivity, urinary recalibration, or prolonged localized swelling, are usually managed through guidance, short-term medication, or outpatient review.

Moderate complications are exceptionally uncommon, and serious adverse outcomes are rare at population scale. When additional support is needed, NovaNex uses scheduled follow-up and early monitoring to identify and address concerns promptly.

Typical follow-up includes

short-stay monitoring before discharge
scheduled clinical review during the first two weeks
functional clearance assessment
continued access to care support if needed

99.5%

recover without
clinical adjustment

0.001%

moderate complications

0.0001%

serious adverse outcomes

Real Stories, Real Confidence

Nora, 22

Series 1

"The first week took some adjustment, but by the third I had completely gotten used to my new body. The only thing I am regretful for is not having done it sooner!"

Renee, 56

Series 1

"I did not choose transformation to become younger. I chose it because curiosity does not disappear just because you have lived a little."

Alina, 34

Series 1

"My sister had hers done two years before me, so I already knew roughly what to expect."

Pricing & Financing

Choose your payment plan

Age at the time of your procedure

How would you like to pay?

Choose a payment term

Choose a down payment

$350

0%50%

Payment summary

Series 1 program fee$8,900.00

Under-27 access credit-$1,900.00

Down payment$350.00

Amount financed$6,650.00

Fixed financing charge$0.00

Setup fee$295.00

$645.00 due initially, then

$184.72/month

$7,295.00 total payable

Book an appointment

Financing provided by Everwell Medical Finance. Eligibility is confirmed before scheduling.

Common Questions

Series 1 is NovaNex's foundational anatomical expansion pathway. It is designed to add integrated phallic anatomy while preserving ovarian, uterine, and endocrine continuity.